2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis
Authors:
- 15 February 2017
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 13 (5) , 415-423
Abstract
Introduction: Crisaborole 2% topical ointment is an anti-inflammatory, non-steroidal phosphodiesterase 4 inhibitor which is currently under investigation for its potential role in the treatment of atopic dermatitis and psoriasis. Areas covered: So far, 7 trials have been completed in atopic dermatitis. The 2% strength appeared to be the superior dosing regimen. Pruritus improved significantly within one week. The improvements in objective efficacy assessments in crisaborole-treated patients were also statistically significant compared to the vehicle. Expert commentary: Crisaborole has several key features in its mode of action which distinguish it from existing treatments for atopic dermatitis (AD), notably its activity against the phosphodiesterase E4 (PDE4) pathway, regulating cyclic AMP (cAMP) levels. This is less immunosuppressive than other pathways and has no effect on skin thinning. The pathway interrupts the itch sensation (pruritus) which means that the itch-scratch cycle, the bane in the life of patients with AD, is interrupted, usually as early as a few days into treatment. Hence, with the promising safety profile demonstrated, early treatment of mild to moderate AD patients might help to control AD better and improve quality of life for patients.Keywords
This publication has 33 references indexed in Scilit:
- Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitisJournal of Allergy and Clinical Immunology, 2012
- Boron‐based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal centerFEBS Letters, 2012
- Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary diseaseBritish Journal of Pharmacology, 2011
- An update on the genetics of atopic dermatitis: Scratching the surface in 2009Journal of Allergy and Clinical Immunology, 2010
- Atopic DermatitisAnnals of Dermatology, 2010
- Global variations in prevalence of eczema symptoms in children from ISAAC Phase ThreeJournal of Allergy and Clinical Immunology, 2009
- Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United KingdomJournal of Allergy and Clinical Immunology, 2009
- Topical Treatments with Pimecrolimus, Tacrolimus and Medium- to High-Potency Corticosteroids, and Risk of LymphomaDermatology, 2009
- Risk of Lymphoma Following Exposure to Calcineurin Inhibitors and Topical Steroids in Patients with Atopic DermatitisJournal of Investigative Dermatology, 2007
- Increased Interleukin-4 Production by Atopic Mononuclear Leukocytes Correlates with Increased Cyclic Adenosine Monophosphate – Phosphodiesterase Activity and Is Reversible by Phosphodiesterase InhibitionJournal of Investigative Dermatology, 1993